ENGLEWOOD, Colo. / Dec 11, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company... Read More

ENGLEWOOD, Colo. / Nov 18, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36 th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.... Read More

ENGLEWOOD, Colo. / Nov 12, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1%... Read More

ENGLEWOOD, Colo. / Oct 17, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m.... Read More

ENGLEWOOD, Colo. / Oct 16, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the Phantom® Fibula Nail System, designed to give surgeons a less invasive option to treat the fibula when patients sustain an ankle fracture. Use of a fibula nail for the treatment of ankle fractures has been... Read More

ENGLEWOOD, Colo. / Sep 10, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a novel Right-Angle Drill to the APEX 3D™ Total Ankle Replacement System designed to improve tibia preparation prior to the implantation of the APEX 3D™ tibia implant. The Right-Angle Drill utilizes a linear... Read More

ENGLEWOOD, Colo. / Sep 04, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the R3FLEX™ Stabilization System, which is designed to restore stability to the ankle syndesmosis after injury from an ankle fracture or high ankle sprain. Ankle fractures are one of the most common injuries... Read More

ENGLEWOOD, Colo. / Aug 14, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is proud to announce the launch of the SMART28℠ Case Management Portal, a cutting-edge platform that leverages AI and a seamless user experience to coordinate patient-specific surgical plans. It is the first major launch of Paragon 28’s SMART28℠... Read More

ENGLEWOOD, Colo. / Aug 08, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Chadi Chahine has been appointed Chief Financial Officer and Executive Vice-President of Supply Chain Operations, effective August 5, 2024. The Company also reported financial results for the quarter ended... Read More

ENGLEWOOD, Colo. / Jul 17, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m.... Read More

ENGLEWOOD, Colo. / May 08, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance. First Quarter 2024 Financial Results Consolidated net revenue for the first quarter of 2024 was a record... Read More

ENGLEWOOD, Colo. / May 02, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright, Interim CFO, will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024, at 5:00 p.m. Pacific Time / 6:00 p.m.... Read More

Stephen Deitsch resigns from his position as Chief Financial Officer to pursue another opportunity; Kristina Wright appointed interim Chief Financial Officer Preliminary, unaudited first quarter 2024 net revenue expected to be in a range of $60.8 to $61.1 million, representing 16.8% to 17.4% reported growth, compared to the prior year period Reaffirms Net Revenue Guidance for Fiscal Year 2024 of $249 to $259 million,... Read More

ENGLEWOOD, Colo. / Mar 28, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler ® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. Upon... Read More

ENGLEWOOD, Colo. / Feb 29, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance. Fourth Quarter and Full Year 2023 Financial Results Consolidated net revenue for the fourth quarter of... Read More

ENGLEWOOD, Colo. / Feb 12, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the CG 2024 Musculoskeletal Conference on Monday, February 12, 2024, at 1:00 p.m. Pacific Time / 2:00 p.m. Mountain Time. A live webcast,... Read More

ENGLEWOOD, Colo. / Feb 06, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time... Read More

ENGLEWOOD, Colo. / Feb 01, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique. The system features an outrigger designed for controlled... Read More

ENGLEWOOD, Colo. / Jan 30, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle. The FJ2000™ Power... Read More

ENGLEWOOD, Colo. / Jan 26, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis longus (“FHL”) or flexor digitorum longus (“FDL”) tendon through a minimally invasive incision, harvesting a working... Read More

ENGLEWOOD, Colo. / Jan 17, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle, Washington. The Bun-Yo-Matic™ is the only bunion solution on the market... Read More

ENGLEWOOD, Colo. / Jan 08, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023. Preliminary unaudited net revenue for the fourth quarter of 2023 is expected to be in a range of $60.3... Read More

ENGLEWOOD, Co. / Jan 05, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler ® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company’s position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond. Both the Grappler ® Knotless Anchor... Read More

ENGLEWOOD, Colo. / Dec 19, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. Pacific Time / 4:00 p.m. Mountain Time. A live webcast, as well as the... Read More

ENGLEWOOD, Colo. / Nov 14, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment and an osteoinductive potential to aid in cellular differentiation and bone formation. These loose cortical... Read More

ENGLEWOOD, Colo. / Nov 14, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System which was developed to provide for increased strength and stability of the osteotomy or fusion site when compared to traditional staple systems. The staples feature an... Read More

ENGLEWOOD, Colo. / Nov 13, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training program making it even more convenient for the company to facilitate on-site surgeon training and education. Paragon 28’s new mobile lab is housed in a 40... Read More

ENGLEWOOD, Colo. / Nov 07, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that it has received a new $150 million credit facility from Ares Capital Corporation (“the Facility”) to replace its existing $90 million senior credit facility. The Facility is comprised of up to $100 million... Read More

ENGLEWOOD, Colo. / Nov 07, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance. Third Quarter 2023 and Nine Months Ended September 30, 2023 Financial Results Consolidated net revenue for... Read More

ENGLEWOOD, Colo. / Nov 03, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting in fireside chats at two upcoming investor conferences. Paragon 28 will participate in the Stephens Annual Investment Conference on November 15, 2023, and the... Read More

ENGLEWOOD, Colo. / Oct 17, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m.... Read More

ENGLEWOOD, Colo. / Sep 11, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28 ® APEX 3D™ Total Ankle... Read More

ENGLEWOOD, Colo. / Aug 28, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain... Read More

ENGLEWOOD, Colo. / Aug 02, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance. Second Quarter 2023 and Six Months Ended June 30, 2023 Financial Results Consolidated net revenue for the... Read More

ENGLEWOOD, Colo. / Jul 28, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.... Read More

ENGLEWOOD, Colo. / Jul 12, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m.... Read More

ENGLEWOOD, Colo. / May 23, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy (SMO) Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies.... Read More

ENGLEWOOD, Colo. / May 04, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance. First Quarter 2023 Financial Results Consolidated net revenue for the first quarter of 2023 was a record $52.0... Read More

ENGLEWOOD, Colo. / Apr 26, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 5:20 p.m. Eastern Time / 3:20 p.m. Mountain... Read More

ENGLEWOOD, Colo. / Apr 24, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals. These osteotomies are preformed to prevent... Read More

ENGLEWOOD, Colo. / Apr 20, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain... Read More

ENGLEWOOD, Colo. / Mar 02, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022. Fourth Quarter and Full Year 2022 Financial Results Consolidated net revenue for the fourth quarter of 2022 was $51.5 million, representing 20.4% and 22.1%... Read More

ENGLEWOOD, Colo. / Feb 17, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today completion of the sale of an additional 975,000 shares of its common stock, pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters in connection with Paragon’s recently... Read More

ENGLEWOOD, Colo. / Feb 16, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.... Read More

ENGLEWOOD, Colo. / Jan 25, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. 3,750,000 shares in... Read More

ENGLEWOOD, Colo. / Jan 25, 2023 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the commencement of a proposed underwritten public offering of 6,500,000 shares of its common stock, consisting of 3,750,000 shares offered by Paragon and 2,750,000 shares offered by certain selling securityholders. Paragon... Read More

Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022. Preliminary unaudited net revenue for the fourth quarter of 2022 is expected to be in a range of $51.2 to $51.5 million, representing reported growth of... Read More